

Special Issue

Nanotherapeutics in Cancer

Message from the Guest Editor

Tumor initiation, growth, and progression rely on the bidirectional interaction of the tumor cells with cellular and noncellular elements in the tumor microenvironment (TME). During the past two decades, extensive studies of the TME biology and its important role in disease progression and prognosis have provided a stage for the design of novel cancer nanomedicines. Clinically used nanotherapeutics, such as liposomal doxorubicin (e.g., Doxil®) and nanoparticle-albumin bound paclitaxel (Abraxane®), utilize changes in the TME, such as the neovasculature-based enhanced permeation and retention (EPR) effect and increased albumin transport, to promote the delivery of chemotherapeutics to the tumor cells. More specific delivery of therapeutics to tumors using concepts of nanomedicine generally yields much better safety profiles and more efficient anti-cancer therapies. In the current Special Issue, entitled “Nanotherapeutics in Cancer”, we aim to cover a collection of current research papers and up-to-date review articles focusing on various aspects of the design of nanomedicines specifically targeted to enhance the safety and efficacy of tumor therapies.

Guest Editor

Dr. Biana Godin

Department of Nanomedicine, Houston Methodist Research Institute,
6670 Bertner Ave., R8-213, Houston, TX, USA

Deadline for manuscript submissions

closed (31 December 2020)



International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/27376

*International Journal of
Molecular Sciences*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ijms@mdpi.com

[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)





International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)



About the Journal

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology, Institute of Nutrition and Food Technology
"Jose Mataix", Biomedical Research Center, University of Granada,
Avda. Conocimiento s/n, 18100 Armilla, Granada, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)